Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin
Authors:
- 1 May 2007
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 12 (4) , 469-476
Abstract
Background: Chronic hepatitis C therapy in HIV patients is often penalized by more frequent premature treatment discontinuations. It is unclear what the relative contribution of more adverse events and/or early virological failures are. Methods: PRESCO was a prospective, multicentre, comparative trial, in which 389 HIV/HCV-coinfected patients with CD4 + T-cell counts >300 cells/ml and elevated aminotransferases received pegylated interferon-α2a (peg IFN-α2a) 180 mg per week plus ribavirin (RBV) 1,000–1,200 mg daily. Patients with HCV genotypes 1 or 4 were treated for 48 or 72 weeks while HCV genotypes 2 or 3 carriers were treated for 24 or 48 weeks. Use of didanosine was not allowed. Results: Sustained virological response (SVR) was achieved by 193 (49.6%), and was significantly greater in HCV-2/3 than in HCV-1/4 patients (72.4% versus 35%; P300 cells/ml most probably explains the lower and different spectrum of serious adverse events in PRESCO compared with prior trials conducted in coinfected patients.Keywords
This publication has 25 references indexed in Scilit:
- Zidovudine use but not weight‐based ribavirin dosing impacts anaemia during HCV treatment in HIV‐infected personsJournal of Viral Hepatitis, 2006
- Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus RibavirinGastroenterology, 2006
- Disseminated cysticercosis involving orbit, brain and subcutaneous tissueJournal of Infection, 2005
- Influence of Hepatitis C Virus Infection on HIV‐1 Disease Progression and Response to Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2005
- SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTSJournal of Hepatology, 2005
- Modelling how ribavirin improves interferon response rates in hepatitis C virus infectionNature, 2004
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patientsAIDS, 2004
- Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected PatientsAIDS Research and Human Retroviruses, 2004
- Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV CoinfectionThe Journal of Infectious Diseases, 2003
- Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected PatientsAIDS Research and Human Retroviruses, 2001